Novel mutations of epidermal growth factor receptor in localized prostate cancer

被引:28
作者
Douglas, Diah A.
Zhong, Hong
Ro, Jae Y.
Oddoux, Carole
Berger, Aaron D.
Pincus, Matthew R.
Satagopan, Jaya M.
Gerald, William L.
Scher, Howard I.
Lee, Peng
Osman, Iman
机构
[1] NYU, Sch Med, Dept Urol, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Mol Genet Program, New York, NY 10016 USA
[4] NYU, Sch Med, Dept Pediat, New York, NY 10016 USA
[5] NY Harbor Healthcare Syst, New York, NY 10010 USA
[6] New York Harbor VA Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA
[7] Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA
[8] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[9] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[10] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[12] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA
[13] Asan Med Ctr, Dept Pathol, Seoul, South Korea
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2006年 / 11卷
关键词
EGFR; mutation; prostate; cancer; adencarcinoma; neoplasia; tumor;
D O I
10.2741/1986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We recently demonstrated that EGFR protein overexpression is more common in African American ( AA) prostate cancer patients compared to Caucasian patients. We further examine EGFR dysregulation by determining EGFR mutation status in the tyrosine kinase ( TK) domain in prostate cancer patients of different ethnicity. Normal and tumor DNA from 89 radical prostatectomy cases were studied for mutations in the EGFR TK domain using genomic DNA sequencing. We identified 4 novel missense mutations in exons 19, 20 and 21 of EGFR TK domain: 3 in Koreans and 1 in Caucasian but none in AA. We also identified 5 distinct synonymous DNA sequence changes, which did not alter the encoded amino acid, in exons 20 and 21 in 31/ 89 ( 35%) patients. Interestingly, these synonymous sequence changes were not observed in normal DNA in 7( 23%) patients, indicating the presence of de novo somatic mutation to a new synonymous sequence. Our data reveal that EGFR missense mutation in the TK domain occurs in localized prostate cancer. Our data also demonstrate the presence of somatic mutation to a new synonymous sequence in a subset of patients. Larger population- based studies are required to define the association between EGFR mutations and the ethnic background of patients.
引用
收藏
页码:2518 / 2525
页数:8
相关论文
共 30 条
[1]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[2]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[3]  
Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438
[4]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[5]   Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study [J].
Havrilesky, L ;
Darcy, KM ;
Hamdan, H ;
Priore, RL ;
Leon, J ;
Bell, J ;
Berchuck, A .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3814-3825
[6]   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].
Kris, MG ;
Natale, RB ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Kelly, K ;
Spiridonidis, H ;
Sandler, A ;
Albain, KS ;
Cella, D ;
Wolf, MK ;
Averbuch, SD ;
Ochs, JJ ;
Kay, AC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158
[7]   Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer [J].
Lee, JW ;
Soung, YH ;
Kim, SY ;
Park, WS ;
Nam, SW ;
Lee, JY ;
Yoo, NJ ;
Lee, SH .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (03) :510-511
[8]   Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck [J].
Lee, JW ;
Soung, YH ;
Kim, SY ;
Nam, HK ;
Park, WS ;
Nam, SW ;
Kim, MS ;
Sun, DI ;
Lee, YS ;
Jang, JJ ;
Lee, JY ;
Lee, SH ;
Yoo, NJ ;
Lee, SH .
CLINICAL CANCER RESEARCH, 2005, 11 (08) :2879-2882
[9]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[10]   EGFR mutations in non-small-cell lung cancer:: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment [J].
Marchetti, A ;
Martella, C ;
Felicioni, L ;
Barassi, F ;
Salvatore, S ;
Chella, A ;
Camplese, PP ;
Iarussi, T ;
Mucilli, F ;
Mezzetti, A ;
Cuccurullo, F ;
Sacco, R ;
Buttitta, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :857-865